Analysts’ Weekly Ratings Updates for Arrowhead Pharmaceuticals (ARWR)

A number of firms have modified their ratings and price targets on shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) recently:

• 7/14/2026 – Arrowhead Pharmaceuticals is now covered by Stifel Nicolaus. They set a “buy” rating and a $98.00 price target on the stock.
• 7/1/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.
• 6/30/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $90.00 price target on the stock.
• 6/27/2026 – Arrowhead Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/17/2026 – Arrowhead Pharmaceuticals had its price target raised by Leerink Partners from $61.00 to $72.00. They now have a “market perform” rating on the stock.
• 5/30/2026 – Arrowhead Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/20/2026 – Arrowhead Pharmaceuticals was downgraded by Weiss Ratings from “hold (c-)” to “sell (d-)”.

Insider Activity

In related news, CFO Daniel Joseph Apel sold 13,095 shares of the stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total value of $934,328.25. Following the completion of the sale, the chief financial officer directly owned 162,905 shares in the company, valued at $11,623,271.75. This represents a 7.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the transaction, the director directly owned 52,012 shares of the company’s stock, valued at approximately $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 26,065 shares of company stock valued at $1,912,662. Insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.